---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-25-036005"
form_type: "8-K/A"
ticker: "NRXP"
cik: "0001719406"
company_name: "NRX Pharmaceuticals, Inc."
filed_at: "2025-11-21T23:59:59+00:00"
generated_at: "2026-05-16T17:39:37.779465+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# NRx Pharmaceuticals amends 8-K to provide acquired Dura Medical's FY2024 financials

## Summary
- Acquisition of Dura Medical closed September 8, 2025; this amendment provides required financials.
- Dura Medical FY2024: net patient revenue $3.26M, net income $505K, total assets $1.37M.
- Dura Medical for six months ended June 30, 2025 (unaudited) also provided.
- Pro forma combined financials filed; reflects impact of acquisition on NRx statements.
- Audited by Weinberg & Company; no material adjustments noted.

## SEC filing metadata
- accession: 0001437749-25-036005
- form_type: 8-K/A
- ticker: NRXP
- cik: 0001719406
- company_name: NRX Pharmaceuticals, Inc.
- filed_at: 2025-11-21T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1719406/000143774925036005/0001437749-25-036005-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1719406/000143774925036005/nrxp20251118_8ka.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-25-036005
- JSON: https://secwatch.observer/filing/0001437749-25-036005.json
- Plain text: https://secwatch.observer/filing/0001437749-25-036005.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.